ClinicalTrials.gg
CompletedNCT04749238Updated Dec 6, 2022

Effect of Extracorporeal Adsorption of Plasma Neutrophil Extracellular Traps (NET) in Sepsis

An interventional study of NucleoCapture device in Sepsis and Sepsis-associated AKI, sponsored by Santersus AG. Completed at 1 site in Russian Federation. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-12-06.

Sponsored by Santersus AG · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Sepsis with a site in Russian Federation — 2 open to participants now, 2 under way, none of them phase 3. Sepsis · Russian Federation.

Enrollment
11th of 11
10 · median 78
Started
2021
with 3 others
No phase
6 of 16
1 open now
Registered
8th of 16
by date
Lead sponsor
1 of 16
Santersus AG

Among the 16 studies in Sepsis with a site in Russian Federation, this one is the 11th largest by enrollment of the 11 interventional ones that give a count, is one of 4 that started in 2021, is one of 6 with no phase, and was the 8th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

2 of the 16 studies in Sepsis with a site in Russian Federation are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Sepsis with a site in Russian Federation, or all of them as a file.
02

Study summary

This open non-randomized controlled single center study investigates to what extent the removal of circulating Neutrophil Extracellular Traps (NETs) from blood by NucleoCapture device has a positive effect on the treatment of patients with sepsis and sepsis-associated AKI (SA-AKI).

Read the detailed description

The term "sepsis" refers to a clinical syndrome in which a dysregulation of the host's inflammatory reaction to infection leads to a life-threatening of organ dysfunctions. Sepsis and septic shock are major causes of death in intensive care units worldwide. Sepsis remains the most important cause of AKI in the intensive care unit (ICU) with 15%-20% of patients with sepsis-associated AKI (SA-AKI) prescribed RRT . In addition to association with short term mortality, AKI is also linked to the later development of CKD, ESRD, and long-term increased risk of death

NETosis is a unique form of neutrophil cell death that is characterized by the release of neutrophil extracellular traps (NETs) composed of DNA web-like structures decorated with highly cytotoxic protein components. Release of NETs leads to bystander tissue damage (including the kidneys) and drives a fatal course of disease in sepsis patients.

The plasmapheresis is a medical procedure, where pathogenic components are being removed from the blood by adsorbers outside the body in an extracorporeal circulation. For removal of the pathogenic substances the plasma is separated from the blood to pass the adsorber. The purified plasma is merged with the solid blood components thereafter and returned to the patient. The NucleoCapture device provide highly selective removal of neutrophil extracellular traps from human blood during plasmapheresis procedure.

03

Conditions studied

  • Sepsis
  • Sepsis-associated AKI

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥ 18 and ≤ 75 years of age.
  • Meet the clinical criteria of sepsis according to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3))
  • Written

Exclusion criteria

Exclusion Criteria:

  • A terminal state
  • Active bleeding or uncontrolled acute massive bleeding
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Treatment with NucleoCapture device

    Device: 100 ml NucleoCapture selective DNA adsorber. Treatment with NucleoCapture in one arm.

    Device: NucleoCapture device

Interventions

  • DeviceNucleoCapture device

    Device: 100 ml NucleoCapture selective DNA adsorber. Treatment with NucleoCapture in one arm

    Also known as: NucleoCapture selective DNA adsorber

06

What researchers measure

Primary outcomes

  1. Incidence of acute kidney injury (AKI)

    Incidence of acute kidney injury (AKI) in accordance with Kidney Disease Improving Global Outcomes (KDIGO) definitions for AKI

    Time frame: from [start of treatment] through 28 days after

  2. Severity of acute kidney injury (AKI)

    Severity of acute kidney injury (AKI) in accordance with KDIGO definitions for AKI

    Time frame: from [start of treatment] through 28 days after

  3. Rate of AKI transition to the more severe stage (for patients with AKI at baseline).

    Rate of worsening of acute kidney injury (AKI) in accordance with KDIGO AKI classification (Changing stages from 1 to 2, from 2 to 3).

    Time frame: from [start of treatment] through 28 days after

  4. Serum creatinine change over time

    Change of creatinine in serum over time for each patient and in average in group

    Time frame: from [start of treatment] through 28 days after

  5. Serum urea change over time

    Change of urea in serum over time for each patient and in average in group

    Time frame: from [start of treatment] through 28 days after

  6. Urine output change

    Change of urine output over time for each patient and in average in group

    Time frame: from [start of treatment] through 28 days after

Secondary outcomes

  1. All-cause mortality

    Mortality for any reasons for each patient and in average in group

    Time frame: from [start of treatment] through 28 days after

  2. SOFA scores change

    Change in SOFA scores over time for each patient and in average in group

    Time frame: from [start of treatment] through 28 days after

  3. qSOFA scores change

    Change in qSOFA scores over time for each patient and in average in group

    Time frame: from [start of treatment] through 28 days after

Other outcomes

  1. Blood level of neutrophil extracellular traps (NETs) change over time

    Change of NETs in blood over time for each patient and in average in group

    Time frame: from [start of treatment] through 28 days after

07

Study locations

1 site
  • North-Western Regional Scientific and Clinical Center named after L.G. Sokolov
    Saint- Petersburg, Russian Federation
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Oct 2021, 8 months.

Of 326 interventional studies with no phase under Sepsis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2021
First posted
Feb 11, 2021
StartActual
Jan 26, 2021
Primary completionActual
Oct 24, 2021
CompletionActual
Oct 24, 2021
Last update
Dec 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04749238
Lead sponsor
Santersus AG
Responsible party
Sponsor
First posted
Feb 11, 2021
Start date
Jan 26, 2021
Primary completion
Oct 24, 2021
Completion
Oct 24, 2021
Last update
Dec 6, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion